Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Knee Osteoarthritis (AMAZE 5)
Latest Information Update: 30 Apr 2026
At a glance
- Drugs Zenagamtide (Primary)
- Indications Obesity; Osteoarthritis
- Focus Registrational; Therapeutic Use
- Acronyms AMAZE 5; AMAZE-5
- Sponsors Novo Nordisk
Most Recent Events
- 27 Apr 2026 Status changed from not yet recruiting to recruiting.
- 23 Mar 2026 New trial record